Founded in 2024, Maryland-based Functional Longevity Labs develops pharmaceutical therapies that target the underlying biology of aging rather than treating age-related diseases one at a time. Its pipeline includes a proprietary small molecule for Alzheimer’s disease and a dietary supplement aimed at age-related decline, built on research into tyrosine metabolism and cellular repair. The company is collaborating with the National Institute on Aging through a Cooperative Research and Development Agreement to develop and test aging-modifying therapeutics.
Cooperative Research and Development Agreement (CRADA) with the National Institute on Aging at NIH
Compliance program
NeuroNascent, IncFounded by neuroscientist Judith Kelleher-Andersson, NeuroNascent is a privately held biotechnology company developing oral small-molecule therapies designed to stimulate the brain’s own neuron regeneration. Its lead candidate, NNI-362, has completed Phase 1a safety testing in healthy older adults and is being advanced for Alzheimer’s and Parkinson’s disease, while the company’s patented discovery platform also supports programs in other neurological disorders. The Clarksville, Maryland company is led by a team with deep experience in central nervous system drug development.CLARKSVILLE, MD
Cognition Therapeutics, IncCognition Therapeutics is a clinical-stage neuroscience company developing oral medicines for age-related neurodegenerative diseases, with its research centered on zervimesine (CT1812), an investigational therapy intended to protect synapses from toxic protein oligomers. The company brings 20 years of mechanistic, translational, and clinical research to Alzheimer’s disease and dementia with Lewy bodies, where its once-daily small-molecule approach is being evaluated in Phase 2 studies. Headquartered in Purchase, New York, Cognition also uses clinical research and patient-caregiver engagement to address conditions that have historically received limited investment.PURCHASE, NY
Diabetes4LivingFounded in 2018 by pharmaceutical and consumer-products executive Gary April, Diabetes4Living develops nutritional supplements for people with diabetes, beginning with its BetiVite daily multivitamin. The company’s formulas are science-based and designed around diabetic nutritional needs, with ingredients such as added sugar, sodium and artificial dyes removed. April brings more than 25 years of industry experience, including launching a branded over-the-counter diabetic-products division before creating Diabetes4Living.
AltimmuneAltimmune is a Gaithersburg-based late-stage clinical biopharmaceutical company developing therapies for serious liver diseases, with its work centered on the investigational dual-action candidate pemvidutide. The company is advancing pemvidutide through clinical programs addressing MASH, alcohol use disorder and alcohol-associated liver disease, pairing direct liver effects with metabolic benefits. Its lead program has received FDA Fast Track designations for MASH and alcohol use disorder, along with Breakthrough Therapy Designation for MASH.GAITHERSBURG, MD